A novel class of ZNF384 aberrations in acute leukemia.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
09 11 2021
Historique:
received: 19 05 2021
accepted: 28 06 2021
pubmed: 17 9 2021
medline: 30 11 2021
entrez: 16 9 2021
Statut: ppublish

Résumé

Fusion of the ZNF384 gene as the 3' partner to several different 5' partner genes occurs recurrently in B-cell precursor acute lymphoblastic and mixed phenotype B/myeloid leukemia. These canonical fusions (ZNF384r) contain the complete ZNF384 coding sequence and are associated with a specific gene expression signature. Cases with this signature, but without canonical ZNF384 fusions (ZNF384r-like cases), have been described previously. Although some have been shown to harbor ZNF362 fusions, the primary aberrations remain unknown in a major proportion. We studied 3 patients with the ZNF384r signature and unknown primary genetic background and identified a previously unknown class of genetic aberration affecting the last exon of ZNF384 and resulting in disruption of the C-terminal portion of the ZNF384 protein. Importantly, in 2 cases, the ZNF384 aberration, indel, was missed during the bioinformatic analysis but revealed by the manual, targeted reanalysis. Two cases with the novel aberrations had a mixed (B/myeloid) immunophenotype commonly associated with canonical ZNF384 fusions. In conclusion, we present leukemia cases with a novel class of ZNF384 aberrations that phenocopy leukemia with ZNF384r. Therefore, we show that part of the so-called ZNF384r-like cases represent the same genetic subtype as leukemia with canonical ZNF384 fusions.

Identifiants

pubmed: 34529760
pii: 476937
doi: 10.1182/bloodadvances.2021005318
pmc: PMC8579251
doi:

Substances chimiques

Trans-Activators 0
Transcription Factors 0
ZNF384 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4393-4397

Informations de copyright

© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Genome Res. 2017 Feb;27(2):185-195
pubmed: 27903646
Nature. 2018 Oct;562(7727):373-379
pubmed: 30209392
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11711-E11720
pubmed: 30487223
Haematologica. 2019 Jul;104(7):1396-1406
pubmed: 30630978
Leukemia. 2021 Nov;35(11):3272-3277
pubmed: 33692463
Leukemia. 2015 Dec;29(12):2445-8
pubmed: 25943178
Nat Genet. 2019 Feb;51(2):296-307
pubmed: 30643249
Haematologica. 2021 Aug 01;106(8):2066-2075
pubmed: 32646889
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Nat Commun. 2016 Nov 08;7:13331
pubmed: 27824051
Haematologica. 2017 Jan;102(1):118-129
pubmed: 27634205
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
EBioMedicine. 2016 Jun;8:173-183
pubmed: 27428428
Genome Biol. 2011 Aug 11;12(8):R72
pubmed: 21835007
N Engl J Med. 2014 Sep 11;371(11):1005-15
pubmed: 25207766
PLoS Comput Biol. 2011 May;7(5):e1001138
pubmed: 21625565

Auteurs

Marketa Zaliova (M)

Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
University Hospital Motol, Prague, Czech Republic.

Lucie Winkowska (L)

Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; and.

Jan Stuchly (J)

Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; and.

Karel Fiser (K)

Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; and.

Petr Triska (P)

Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; and.

Martina Zwyrtkova (M)

Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; and.

Ondrej Hrusak (O)

Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
University Hospital Motol, Prague, Czech Republic.

Julia Starkova (J)

Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
University Hospital Motol, Prague, Czech Republic.

Lucie Sramkova (L)

Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; and.
University Hospital Motol, Prague, Czech Republic.

Jan Stary (J)

Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; and.
University Hospital Motol, Prague, Czech Republic.

Jan Trka (J)

Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
University Hospital Motol, Prague, Czech Republic.

Jan Zuna (J)

Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
University Hospital Motol, Prague, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH